Eric Joseph Daniels - 06 Mar 2026 Form 4 Insider Report for KIORA PHARMACEUTICALS INC (KPRX)

Reporting relationship: Chief Development Officer
Issuer ticker: KPRX
Reported as of: 06 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 10 Mar 2026, 16:37:12 UTC
Prior SEC filing: 06 Mar 2026
Next SEC filing: 02 Apr 2026
Source filing: View source filing
Reporting owner signature: /s/ Melissa Tosca, Attorney-in-Fact

Key filing fact

Eric Joseph Daniels filed Form 4 for KIORA PHARMACEUTICALS INC (KPRX) on 10 Mar 2026.

Key facts

This page summarizes Eric Joseph Daniels's Form 4 filing for KIORA PHARMACEUTICALS INC (KPRX).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 10 Mar 2026, 16:37.

Change

Previous filing in this sequence was filed on 06 Mar 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001892943 Primary reporting owner

Daniels Eric Joseph

Relationship: Chief Development Officer
Address: C/O KIORA PHARMACEUTICALS, INC., 169 SAXONY RD., SUITE 212, ENCINITAS
Signature: /s/ Melissa Tosca, Attorney-in-Fact
Signature date: 10 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

KPRX transaction

Common Stock

Award

Transaction value
Shares: +6,533
Change %: +25%
Price: $0.000000^*
Shares after: 32,670
Date: 06 Mar 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

KPRX transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +13,067
Change %
Price: $0.000000^*
Shares after: 13,067
Date: 06 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 13,067
Exercise price: $1.98
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Grant of restricted stock from the Issuer pursuant to the Issuer's 2024 Equity Incentive Plan (the "Plan"). The restrictions will vest as to one-third (1/3) of the shares on each of April 1, 2027, April 1, 2028 and April 1, 2029, subject to the reporting person's continuous service through each such vesting date.

Footnote F2

The reporting person received an option to purchase Common Stock from the Issuer pursuant to the Plan. The option will become exercisable as to one-third (1/3) of the shares underlying the Option on April 1, 2027, and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years, subject to the reporting person's continuous service through each such vesting date.